Story
Zealand Pharma Stock Falls Over 11% on Obesity Drug's Side Effect Concerns

Shares of Zealand Pharma (ZELA) plunged 11.7% after its partner, Boehringer Ingelheim, released Phase III trial data for the obesity drug candidate survodutide. While the drug successfully met its primary efficacy goals, investors focused on a high patient dropout rate due to side effects, raising concerns about its commercial viability in a competitive market.
Trial Data Raises Tolerability Questions
The SYNCHRONIZE-2 trial data, presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes and published in the New England Journal of Medicine, showed that survodutide met its co-primary endpoints.
Key findings from the 76-week trial include:
- Patients achieved an average body weight reduction of up to 13.1%, compared to 3.1% for those on placebo.
- Up to 79.3% of patients treated with survodutide lost at least 5% of their body weight.
AdHowever, the data also revealed a significant tolerability issue. 18% of patients on survodutide discontinued the treatment due to gastrointestinal side effects, including nausea, vomiting, and diarrhea. This figure was substantially higher than the 1.2% discontinuation rate in the placebo group.
Market Impact and Competitive Landscape
The high dropout rate rattled investors, who are closely watching for potential differentiators in the crowded market for obesity treatments. With several effective therapies already available, a drug's tolerability profile is seen as a critical factor for patient adherence and long-term commercial success.
Zealand Pharma licensed survodutide, a glucagon/GLP-1 receptor dual agonist, to Boehringer Ingelheim. The Danish firm's future revenue from the drug is dependent on achieving development milestones and earning royalties on sales. The market's skepticism about survodutide's ability to compete translated directly into selling pressure on Zealand's shares, pushing the stock price toward its 52-week low.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.